1-20 of 67
Connie Lee Batlevi
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Assessment of the prognostic value of FDG PET-derived markers and responses in POLARIX

Free
Anne-Ségolène Cottereau, Alex Herrera, Hervé Tilly, Gilles Salles, Loïc Chartier, Matthew Sugidono, Skander Jemaa, Richard Carano, Connie Lee Batlevi, Greg Hapgood, Georg Lenz, Franck Morschhauser
Journal: Blood
Blood (2025) 146 (Supplement 1): 5329.
https://doi.org/10.1182/blood-2025-5329
Published: 2025
Journal Articles

Fixed-duration intravenous mosunetuzumab plus polatuzumab vedotin combination therapy continues to demonstrate durable responses in patients with large B-cell lymphoma: 3-year follow-up from a Phase Ib/II study

Free
Manali Kamdar, Julio Chavez, Adam Olszewski, Sarit Assouline, Izidore S. Lossos, Catherine Diefenbach, Dipenkumar Modi, Waleed Sabry, Seema Naik, Amitkumar Mehta, Sneha Makadia, Song Pham, Elicia Peneul, Hao Wu, Wahib S. Ead, Iris To, Dennis J. Houston, Connie Lee Batlevi, Elizabeth Budde
Journal: Blood
Blood (2025) 146 (Supplement 1): 3735.
https://doi.org/10.1182/blood-2025-3735
Published: 2025
Journal Articles

A single-cell co-expression score of MYC and BCL2 identifies high-risk BCR-addicted DLBCL benefiting from polatuzumab vedotin in the POLARIX trial

Free
Shruti Sridhar, Will Harris, Chartsiam Tipgomut, Qiang Pan-Hammarstrom, Gilles Salles, Alex Herrera, Marek Trneny, Franck Morschhauser, Connie Lee Batlevi, Matthew Sugidono, Yanwen Jiang, Georg Lenz, Anand Devaprasath Jeyasekharan
Journal: Blood
Blood (2025) 146 (Supplement 1): 3522.
https://doi.org/10.1182/blood-2025-3522
Published: 2025
Journal Articles

Transcriptional profiling refines DLBCL classification and identifies subtypes with distinct therapeutic vulnerabilities

Free
James Godfrey, Sravya Tumuluru, Alan Cooper, Gilles Salles, Marek Trneny, Georg Lenz, Franck Morschhauser, Fabrice Jardin, Will Harris, Sandhya Balasubramanian, Matthew Sugidono, Connie Lee Batlevi, Yanwen Jiang, Justin Kline, Alex Herrera
Journal: Blood
Blood (2025) 146 (Supplement 1): 49.
https://doi.org/10.1182/blood-2025-49
Published: 2025
Journal Articles

Real-world use of Pola-R-CHP for untreated diffuse large B-cell lymphoma (DLBCL): A systematic literature review

Free
Peng Liu, Koji Kato, Sai Li, Lara Chayab, Adriano Sa, Connie Lee Batlevi, Matthew Matasar
Journal: Blood
Blood (2025) 146 (Supplement 1): 8082.
https://doi.org/10.1182/blood-2025-8082
Published: 2025
Journal Articles

Characterizing the US Patient Population Receiving Rituximab with Gemcitabine and Oxaliplatin (R-GemOx) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Using Real-World Data

Free
Lihua E. Budde, Adam J. Olszewski, Bei Hu, Nikesh Shah, Connie Lee Batlevi, Shen Yin, Iris To, Michael C. Wei, Martine Kallemeijn, Victor Orellana-Noia, Lisa Musick, Natasha Shamas, Navdeep Pal, Ashwini Shewade, Jason R. Westin
Journal: Blood
Blood (2024) 144 (Supplement 1): 2373.
https://doi.org/10.1182/blood-2024-194340
Published: 2024
Journal Articles

A Randomized Phase II Study of Mosunetuzumab SC Plus Polatuzumab Vedotin Demonstrates Improved Outcomes Versus Rituximab Plus Polatuzumab Vedotin in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Free
Julio C. Chavez, Adam J. Olszewski, Mariana Bastos-Oreiro, Sarit E. Assouline, Izidore S. Lossos, Catherine Diefenbach, Nilanjan Ghosh, Dipenkumar Modi, Waleed Sabry, Seema Naik, Nirav N. Shah, Ronan Foley, Daniel J Hodson, Sneha Makadia, Song Pham, Elicia Penuel, Hao Wu, Wahib S. Ead, Iris To, Connie Lee Batlevi, Michael C. Wei, L. Elizabeth Budde
Journal: Blood
Blood (2024) 144 (Supplement 1): 989.
https://doi.org/10.1182/blood-2024-194581
Published: 2024
Journal Articles

Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with R-GemOx: A Multi-Center Retrospective Cohort Study

Free
Samuel Yamshon, Jean L. Koff, Melissa C. Larson, Brad S. Kahl, Carla Casulo, Izidore S. Lossos, Sara Haddadi, Michele D. Stanchina, Dai Chihara, Amy A. Ayers, Thomas M. Habermann, Yucai Wang, Arushi Khurana, Grzegorz S. Nowakowski, Tanner W Reicks, Umar Farooq, Brian K. Link, Jonathon B. Cohen, Peter Martin, Jia Li, Ashwini Shewade, Connie Lee Batlevi, Andrea Lo-Rossi, David Fox, Anthony Masaquel, Yong Mun, James R. Cerhan, Christopher R. Flowers, Matthew J. Maurer, Loretta Nastoupil
Journal: Blood
Blood (2024) 144 (Supplement 1): 3093.
https://doi.org/10.1182/blood-2024-208111
Published: 2024
Journal Articles

Rituximab +/- Ibrutinib As First Line Therapy for Marginal Zone Lymphoma

Free
Ariela Noy, Win Su Thet, Shreya Vemuri, Venkatraman Seshan, Connie Lee Batlevi, Zachary D. Epstein-Peterson, Lorenzo Falchi, Paola Ghione, Thomas M. Habermann, Paul A. Hamlin, Erel Joffe, Jennifer Kimberly Lue, Matthew Matasar, Maria Lia Palomba, Andrew D. Zelenetz, Gilles Salles
Journal: Blood
Blood (2024) 144 (Supplement 1): 6352.
https://doi.org/10.1182/blood-2024-211730
Published: 2024
Journal Articles

Deep Learning Predicts Risk of Large B-Cell Lymphoma Progression upon R-CHOP Therapy from Baseline Histology

Free
Samaneh Abbasi Sureshjani, Anil Yüce, Christian Doerig, Agata Mosinska, Patrick Kimes, Murali Kesavan, Connie Lee Batlevi, Yanwen Jiang, Markus D Herrmann
Journal: Blood
Blood (2024) 144 (Supplement 1): 108.
https://doi.org/10.1182/blood-2024-203029
Published: 2024
Journal Articles

Five-Year Analysis of the POLARIX Study: Prolonged Follow-up Confirms Positive Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) on Outcomes

Free
Gilles Salles, Franck Morschhauser, Laurie H. Sehn, Alex F. Herrera, Jonathan W. Friedberg, Marek Trněný, Georg Lenz, Jeff P. Sharman, Charles Herbaux, John M. Burke, Matthew Matasar, Graham P. Collins, Yuqin Song, Antonio Pinto, Shinya Rai, Koji Izutsu, Calvin Lee, Saibah Chohan, Matthew Sugidono, Yanwen Jiang, Connie Lee Batlevi, Mark Yan, Jamie Hirata, Hervé Tilly, Christopher R. Flowers
Journal: Blood
Blood (2024) 144 (Supplement 1): 469.
https://doi.org/10.1182/blood-2024-197938
Published: 2024
Journal Articles

Fixed Duration Mosunetuzumab Plus Polatuzumab Vedotin Has Promising Efficacy and a Manageable Safety Profile in Patients with BTKi Relapsed/Refractory Mantle Cell Lymphoma: Initial Results from a Phase Ib/II Study

Free
Michael L. Wang, Sarit Assouline, Manali Kamdar, Nilanjan Ghosh, Seema Naik, Shazia K. Nakhoda, Julio C. Chavez, Ting Jia, Song Pham, Ling-Yuh Huw, Jing Jing, Wahib Ead, Iris To, Connie Lee Batlevi, Michael C. Wei, L. Elizabeth Budde
Journal: Blood
Blood (2023) 142 (Supplement 1): 734.
https://doi.org/10.1182/blood-2023-174956
Published: 2023
Journal Articles

Mosunetuzumab and Polatuzumab Vedotin Demonstrates Preliminary Efficacy in Elderly Unfit/Frail Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Free
Adam J Olszewski, Herbert Eradat, Abraham Avigdor, Netanel A. Horowitz, Sunil Babu, Itai Levi, Matthew McKinney, Seung Tae Lee, Juan Miguel Bergua Burgues, Antonia Rodriguez Izquierdo, Mariana Bastos-Oreiro, Chezi Ganzel, Tae Min Kim, Youngwoo Jeon, Michal Taszner, Mayur Narkhede, Won Seog Kim, Ho-Jin Shin, David Lavie, Dariusz Woszczyk, Diana Dunshee, Amy V. Kapp, Mingzhu Zhou, Connie Lee Batlevi, Wahib Ead, Gila Sellam, Wojciech Jurczak
Journal: Blood
Blood (2023) 142 (Supplement 1): 855.
https://doi.org/10.1182/blood-2023-177588
Published: 2023
Journal Articles

Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma

Free
Clinical Trials & Observations
Claire Roddie, Lazaros J. Lekakis, Maria A. V. Marzolini, Aravind Ramakrishnan, Yiyun Zhang, Yanqing Hu, Vijay G. R. Peddareddigari, Nushmia Khokhar, Robert Chen, Silvia Basilico, Meera Raymond, Frederick Arce Vargas, Kevin Duffy, Wolfram Brugger, Maeve A. O’Reilly, Leigh Wood, David C. Linch, Karl S. Peggs, Carlos Bachier, Elizabeth Lihua Budde, Connie Lee Batlevi, Nancy Bartlett, David Irvine, Eleni Tholouli, Wendy Osborne, Kirit M. Ardeshna, Martin A. Pule
Journal: Blood
Blood (2023) 141 (20): 2470–2482.
https://doi.org/10.1182/blood.2022018598
Published: 2023
Includes: Supplemental data
Journal Articles

Tafasitamab and Lenalidomide in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL): Real World Outcomes in a Multicenter Retrospective Study

Free
David Qualls, Michael J Buege, Phuong Dao, Paolo F. Caimi, Sarah C. Rutherford, Graham Wehmeyer, Jason T. Romancik, Lori A. Leslie, Mwanasha H. Merrill, Jennifer L. Crombie, Behzad Amoozgar, Brad S. Kahl, David A. Bond, Kami J. Maddocks, Michelle Okwali, Venkatraman Seshan, Gilles Salles, Connie Lee Batlevi
Journal: Blood
Blood (2022) 140 (Supplement 1): 787–789.
https://doi.org/10.1182/blood-2022-167620
Published: 2022
Journal Articles

Predictors and Implications of Renal Injury in Large Cell Lymphoma Patients Receiving CD19 CAR T Cell Therapy

Free
Alexander P. Boardman, Victoria Gutgarts, Jessica R. Flynn, Sean M. Devlin, Ana Alarcon Tomas, Joshua A. Fein, John Slingerland, Allison Parascondola, Richard J. Lin, Michael Scordo, Connie Lee Batlevi, Parastoo B. Dahi, Sergio A. Giralt, M.Lia Palomba, Gilles Salles, Karthik Nath, Moneeza Walji, Magdalena Corona De Lapuerta, Gunjan L. Shah, Miguel-Angel Perales, Insara Jaffer-Sathick, Roni Shouval
Journal: Blood
Blood (2022) 140 (Supplement 1): 4671–4672.
https://doi.org/10.1182/blood-2022-157455
Published: 2022
Journal Articles

Characterization of a Large Cohort of Patients with Nodal Marginal Zone Lymphoma Shows Prolonged Survival, Time-to-Treatment, and Time-to-Transformation

Free
Robert Stuver, Esther Drill, David Qualls, Michelle Okwali, Connie Lee Batlevi, Philip C Caron, Zachary D. Epstein-Peterson, Lorenzo Falchi, Audrey Hamilton, Paul A. Hamlin, Steven M. Horwitz, Andrew M. Intlekofer, William T. Johnson, Niloufer Khan, Oscar B Lahoud, Jennifer Kimberly Lue, Matthew J. Matasar, Alison J. Moskowitz, Ariela Noy, M.Lia Palomba, Santosha Vardhana, Andrew D. Zelenetz, Gilles Salles, David J. Straus
Journal: Blood
Blood (2022) 140 (Supplement 1): 9380–9382.
https://doi.org/10.1182/blood-2022-156383
Published: 2022
Journal Articles

Enitociclib (VIP152/formerly BAY1251152) Is a Selective and Active CDK9 Inhibitor : Preliminary Safety and Early Signs of Efficacy in Patients with Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Free
Mazyar Shadman, Anthony R. Mato, Connie Lee Batlevi, Ian W. Flinn, Martin Gutierrez, Marc Uemura, Don A. Stevens, Daniel Morillo, John C. Byrd, Melanie M. Frigault, George Clemens, Xin Huang, Raquel Izumi, Harvey Wong, Renee Breed, Hermes Garban, Amy J. Johnson, Beatrix Stelte-Ludwig, Arushi Mithal, Joseph Birkett, Ahmed Hamdy, Kerry A. Rogers
Journal: Blood
Blood (2022) 140 (Supplement 1): 9454–9456.
https://doi.org/10.1182/blood-2022-167651
Published: 2022
Journal Articles

Immune Signature of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma

Free
Beatriz Wills, Nivetha Ganesan, Gunjan L. Shah, Phillip Wong, Kimon V. Argyropoulos, Filiz Sen, Ahmet Dogan, David J. Straus, Ariela Noy, Anita Kumar, Heiko Schoder, Laure Michaud, Maria Lia Palomba, Lorenzo Falchi, Oscar B Lahoud, Paul A. Hamlin, Joachim Yahalom, William T. Johnson, Andrew D. Zelenetz, Andrew M. Intlekofer, Colette Owens, Connie Lee Batlevi, Audrey Hamilton, Philip C Caron, Steven M. Horwitz, Natasha Galasso, Helen Hancock, Theresa Davey, Alayna Santarosa, Leslie Perez, Charisse Capadona, Brittney Munayirji, Matthew J. Matasar, Georgios Pongas, Ellie Casper, Gilles Salles, Craig H. Moskowitz, Santosha Vardhana, Alison J. Moskowitz
Journal: Blood
Blood (2022) 140 (Supplement 1): 9286–9288.
https://doi.org/10.1182/blood-2022-160206
Published: 2022
Journal Articles

LymphGen Classification of Diffuse Large B-Cell Lymphoma in a Cohort of Adolescent and Young Adult (AYA) Patients

Free
Angelo Cabal, Menglei Zhu, Manik Uppal, Erel Joffe, Connie Lee Batlevi, Matthew J. Matasar, Michelle Okwali, Ahmet Dogan, Andrew D. Zelenetz, Gilles Salles, Niloufer Khan
Journal: Blood
Blood (2022) 140 (Supplement 1): 6392–6393.
https://doi.org/10.1182/blood-2022-162418
Published: 2022